Bruker Corporation · NASDAQ:BRKR

Bruker — Jefferies Virtual Healthcare Conference 2021

16 slides from Bruker's conference presentation, Jun 2, 2021

  1. Slide 1: Jefferies Virtual Healthcare Conference: Bruker Corporation

    JEFFERIES VIRTUAL HEALTHCARE CONFERENCE Bruker Corporation Nasdaq: BRKR Frank H. Laukien, PhD, President & CEO Juergen Srega, President, Bruker CALID Group June 2, 2021

  2. Slide 2: Safe Harbor Statement

    BRUKER CORP ORATI ON Safe Harbor Statement Any statements contained in this presentation which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 193

  3. Slide 3: Q1 2021: Business and Market Recovery Lead to Significant Step Ups in Revenues, Margins and EPS

    Q1 2021 BUSINESS UP DATE Q1 2021: Business and Market Recovery Lead to Significant Step Ups in Revenues, Margins and EPS Q1 2021 Performance Year-over-Year Q1 Financials ❖ Revenues increase $130.7M, or +30.8% Revenues [$M] ▪ Organic growth of +23.8%, with BSI up +25.6% and BEST up +7.1% 554.7 +30.8%

  4. Slide 4: Raising FY 2021 Non-GAAP Organic Revenue Growth Guidance

    Q2 2021 AND F ISCAL YEAR 2 0 2 1 OUTLOOK UP DATE Raising FY 2021 Non-GAAP Organic Revenue Growth Guidance On Continued Strong Demand for Our Instruments and Solutions Q2 2021 Non-GAAP Organic Growth FY 2021 Non-GAAP Organic Growth Outlook: Guidance: UPDATED: 25% or greater year-over-year UPDATED: 13

  5. Slide 5: Project Accelerate 2.0

    BRUKER 2021 AN D BEYON D Project Accelerate 2.0 Differentiated, High Value, Innovative Expanded Strategy & Incremental TAMs: ▪ Unbiased Proteomics & Multiomics: $5-6B TAM Life Science Research & Diagnostic ▪ Spatial Biology & Single-Cell Multiomics: $3-5B TAM Solutions ▪ Microbiology & Molecular Dx:

  6. Slide 6: Faster growth from six expanded high-growth, high-margin initiatives

    P ROJECT ACCELERATE 2 .0 Faster growth from six expanded high-growth, high-margin initiatives Unbiased 4D Proteomics & Consumables, Software, Unbiased 4D Multiomics, Functional Service & Aftermarket Proteomics & Structural Biology Consumables, assays, services, Multiomics MS and NMR solutions for li

  7. Slide 7: Unbiased True Single Cell 4D Proteomics

    UN BIASED 4D P ROTEOM ICS & 4 D M ULTIOMICS Unbiased True Single Cell 4D Proteomics Bruker launches ultra-high sensitivity timsTOF trueSCP for unbiased, quantitative single-cell 4D Proteomics “I always said that single cell proteomics would not happen in my lifetime, but I’m happy to have been prove

  8. Slide 8: Introducing the timsTOF Pro 2 (4D Proteomics)

    UN BIASED 4D P ROTEOM ICS & 4 D M ULTIOMICS Introducing the The standard for high throughput, high sensitivity, 4D Proteomics improved 30 min “Since we started to work with the timsTOF Pro in February 2019, we have run more than 25,000 samples, of which about 5,000 have been non-depleted plasma dige

  9. Slide 9: Canopy quantitative, high-resolution spatial biology & targeted single-cell multiomics research

    SP ATIAL BIOLOG Y, SIN G LE -CELL OM ICS, AND CELLULAR ANALYSIS Canopy quantitative, high-resolution spatial biology & targeted single-cell multiomics research true single-cell resolution Bruker ChipCytometry™: Quantitative Spatial Biology & Single-Cell Targeted Proteomics 8-log PD-1 expression in H

  10. Slide 10: Acuity Spatial Genomics For In Situ Spatial 3D Genomics

    SP ATIAL BIOLOG Y, SIN G LE -CELL OM ICS, AND CELLULAR ANALYSIS Acuity Spatial Genomics For In Situ Spatial 3D Genomics New venture, majority-owned by Bruker, opening a new frontier in spatial 3D genomics and multiomic analyses for discovery ▪ Leverages patented innovations developed in the lab of T

  11. Slide 11: Molecular Phenomics Research Tools Enabling Insights into 'Long COVID'

    P H ENOMICS RESEARCH Molecular Phenomics Research Tools Enabling Insights into ‘Long COVID’ and Post-Acute Metabolic Abnormalities Quantitative NMR and Mass Spec Assay Platform for Risk Assessment and Longitudinal Monitoring of Post-Acute COVID-19 Syndrome (PACS)(1) Research collaboration between Au

  12. Slide 12: Appendix

    JEFFERIES VIRTUAL HEALTHCARE CONFERENCE Appendix

  13. Slide 13: Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)

    BRUKER CORP ORATI ON Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) (1) Bruker Scientific Instruments (BSI) revenue reflects the sum of the BSI Life Science and BSI Nano Segments as presented in our 2020 Form 10-K. © 2021 Bruker + - confidential Jefferies Virtual Healthcare Confer

  14. Slide 14: Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)

    BRUKER CORP ORATI ON Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) © 2021 Bruker + - confidential Jefferies Virtual Healthcare Conference | June 2, 2021 | 14

  15. Slide 15: Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)

    BRUKER CORP ORATI ON Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) © 2021 Bruker + - confidential Jefferies Virtual Healthcare Conference | June 2, 2021 | 15

  16. Slide 16: ;

    ;

Bruker — Jefferies Virtual Healthcare Conference 2021 on 6ix